Chromium/biotin treatment of type II diabetes

Abstract

A method for treating Type II diabetes by administering to an affected individual a combination of chromic tripicolinate and biotin. The two compounds are administered orally or parenterally at in daily dosages which provide between 50 and 1,000 μg of chromium and between 25 μg and 200 mg biotin, the amounts of chromium and biotin being selected together to provide a greater than additive effect.

1. A method for reducing hyperglycemia and stabilizing the level of serum glucose comprising administering to an individual in need thereof between about 50 to 1,000 micrograms per day of chromium as synthetic chromic tripicolinate in combination with between about 25 μg and 200 mg per day of biotin, wherein the amounts of chromic tripicolinate and biotin are selected together to provide a greater than additive effect. 
     
     
       2. The method of  claim 1 , comprising administering between about 500 and 1,000 micrograms per day of chromium as synthetic chromic tripicolinate. 
     
     
       3. The method of  claim 1 , comprising administering between about 1 mg and 100 mg biotin per day. 
     
     
       4. The method of  claim 1 , wherein said chromic tripicolinate is in a pharmaceutically acceptable carrier. 
     
     
       5. The method of  claim 1 , wherein said biotin is in a pharmaceutically acceptable carrier. 
     
     
       6. The method of  claim 1 , wherein said chromic tripicolinate is orally administered. 
     
     
       7. The method of  claim 1 , wherein said biotin is orally administered. 
     
     
       8. The method of  claim 1 , wherein said chromic tripicolinate is parenterally administered. 
     
     
       9. The method of  claim 1 , wherein said biotin is parenterally administered. 
     
     
       10. A pharmaceutical composition comprising chromium as synthetic chromic tripicolinate and biotin, wherein the ratio of chromium to biotin is between about 2:1 and 1:200 (w/w), wherein the amounts of chromic tripicolinate and biotin are selected together to provide a greater than additive effect. 
     
     
       11. A method for reducing blood glucose levels comprising administering to an individual in need thereof between about  50  and  1 , 000  micrograms per day of chromium as synthetic chromic tripicolinate in combination with between about  25  μg and  200  mg per day of biotin, wherein the amounts of chromic tripicolinate and biotin are selected together to provide a synergistic effect in reducing blood glucose levels. 
     
     
       12. A method for reducing blood glucose levels comprising administering to an individual in need thereof a composition consisting essentially of between about  50  and  1 , 000  micrograms per day of chromium as synthetic chromic tripicolinate in combination with between about  25  micrograms and  200  milligrams per day of biotin, wherein the amounts of chromic tripicolinate and biotin are selected together to provide a synergistic effect in reducing blood glucose levels. 
     
     
       13. The method of  claim 12 , wherein the individual is a human. 
     
     
       14. The method of  claim 12 , comprising administering between about  500  and  1 , 000  micrograms per day of chromium as synthetic chromic tripicolinate. 
     
     
       15. The method of  claim 12 , comprising administering between about  1  milligram and  100  milligrams biotin per day. 
     
     
       16. The method of  claim 12 , comprising administering about  600  micrograms of chromium as synthetic chromic tripicolinate and about  300  micrograms of biotin, wherein the amounts of chromic tripicolinate and biotin are selected together to provide a synergistic effect in reducing blood glucose levels. 
     
     
       17. The method of  claim 12 , comprising administering about  400  micrograms of chromium as synthetic chromic tripicolinate and about  200  micrograms of biotin, wherein the amounts of chromic tripicolinate and biotin are selected together to provide a synergistic effect in reducing blood glucose levels. 
     
     
       18. The method of  claim 12 , wherein said chromic tripicolinate is in a pharmaceutically acceptable carrier. 
     
     
       19. The method of  claim 12 , wherein said biotin is in a pharmaceutically acceptable carrier. 
     
     
       20. The method of  claim 12 , wherein said chromic tripicolinate is orally administered. 
     
     
       21. The method of  claim 12 , wherein said biotin is orally administered. 
     
     
       22. The method of  claim 12 , wherein said chromic tripicolinate is parenterally administered. 
     
     
       23. The method of  claim 12 , wherein said biotin is parenterally administered. 
     
     
       24. A pharmaceutical composition consisting essentially of chromium as synthetic chromic tripicolinate and biotin, wherein the ratio of chromium to biotin is between about  2 : 1  and  1 : 200  ( w/w ),  wherein the amounts of chromic tripicolinate and biotin are selected together to provide a synergistic effect in reducing blood glucose levels.   
     
     
       25. A pharmaceutical composition comprising about  600  micrograms/day of chromium as synthetic chromic tripicolinate and about  300  micrograms/day of biotin, wherein the amounts of chromic tripicolinate and biotin are selected together to provide a synergistic effect in reducing blood glucose levels. 
     
     
       26. A pharmaceutical composition consisting essentially of about  600  micrograms/day of chromium as synthetic chromic tripicolinate and about  300  micrograms/day of biotin, wherein the amounts of chromic tripicolinate and biotin are selected together to provide a synergistic effect in reducing blood glucose levels.